265 related articles for article (PubMed ID: 28471725)
21. Controversies and role of HPV16 in recurrent/metastatic squamous cell cancers of the head and neck.
Misiukiewicz K; Bonomi M; Demicco E; Posner M
Ann Oncol; 2014 Aug; 25(8):1667-8. PubMed ID: 24875798
[No Abstract] [Full Text] [Related]
22. Prognostic role of epiregulin/amphiregulin expression in recurrent/metastatic head and neck cancer treated with cetuximab.
Kogashiwa Y; Inoue H; Kuba K; Araki R; Yasuda M; Nakahira M; Sugasawa M
Head Neck; 2018 Nov; 40(11):2424-2431. PubMed ID: 30302873
[TBL] [Abstract][Full Text] [Related]
23. The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab
Baysal H; De Pauw I; Zaryouh H; Peeters M; Vermorken JB; Lardon F; De Waele J; Wouters A
Front Immunol; 2021; 12():737311. PubMed ID: 34557197
[TBL] [Abstract][Full Text] [Related]
24. Phase III Randomized Study of Induction Chemotherapy Followed by Definitive Radiotherapy + Cetuximab Versus Chemoradiotherapy in Squamous Cell Carcinoma of Head and Neck: The INTERCEPTOR-GONO Study (NCT00999700).
Merlano MC; Denaro N; Vecchio S; Licitra L; Curcio P; Benasso M; Bagicalupo A; Numico G; Russi E; Corvo' R; Bruzzi P;
Oncology; 2020; 98(11):763-770. PubMed ID: 32629446
[TBL] [Abstract][Full Text] [Related]
25. Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinoma-A single institution analysis of 54 patients.
Sukari A; Nagasaka M; Diab M; Al Sibai K; Atassi B; Elayoubi JA; Kim S; Küçük Ö
Clin Otolaryngol; 2019 Jul; 44(4):639-643. PubMed ID: 30784192
[No Abstract] [Full Text] [Related]
26. Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
El Rassy E; Assi T; Bakouny Z; El Karak F; Pavlidis N; Ghosn M
Future Oncol; 2019 Mar; 15(8):909-923. PubMed ID: 30669875
[TBL] [Abstract][Full Text] [Related]
27. Progression beyond nivolumab: Stop or repeat? Dramatic responses with salvage chemotherapy.
Daste A; De-Mones E; Cochin V; Dupin C; Digue L; Ravaud A; Domblides C
Oral Oncol; 2018 Jun; 81():116-118. PubMed ID: 29703607
[No Abstract] [Full Text] [Related]
28. A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer.
Brisson RJ; Kochanny S; Arshad S; Dekker A; DeSouza JA; Saloura V; Vokes EE; Seiwert TY
Head Neck; 2019 Nov; 41(11):3842-3849. PubMed ID: 31486207
[TBL] [Abstract][Full Text] [Related]
29. Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Fushimi C; Baba D; Masubuchi T; Yamazaki M; Kitani Y; Kitajima T; Tanaka J; Hanyu K; Tanaka N; Miura K; Tada Y
In Vivo; 2020; 34(5):2653-2657. PubMed ID: 32871796
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
[TBL] [Abstract][Full Text] [Related]
31. Palliative chemotherapy with or without cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: Indian tertiary care retrospective analysis.
Bahl A; Bhatia K; Choudhary P; Singhla S; Shrivastava G; Bal J; Anand AK; Chaturvedi H; Dua B
Head Neck; 2020 May; 42(5):955-962. PubMed ID: 31916340
[TBL] [Abstract][Full Text] [Related]
32. Maintenance Therapy with Biweekly Cetuximab: Optimizing Schedule Can Preserve Activity and Improves Compliance in Advanced Head and Neck Cancer.
Addeo R; Montella L; Mastella A; Vincenzi B; Mazzone S; Ricciardiello F; Del Prete S
Oncology; 2018; 95(6):353-359. PubMed ID: 30184543
[TBL] [Abstract][Full Text] [Related]
33. Nivolumab in squamous cell carcinoma of the head and neck.
Specenier P
Expert Rev Anticancer Ther; 2018 May; 18(5):409-420. PubMed ID: 29560755
[TBL] [Abstract][Full Text] [Related]
34. The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma.
da Costa AABA; Costa FD; Araújo DV; Camandaroba MPG; de Jesus VHF; Oliveira A; Alves ACF; Stecca C; Machado L; de Oliveira ACF; de Oliveira TB; Nicolau UR; de Lima VCC
Med Oncol; 2018 Nov; 36(1):8. PubMed ID: 30478503
[TBL] [Abstract][Full Text] [Related]
35. Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy.
Siano M; Infante G; Resteghini C; Cau MC; Alfieri S; Bergamini C; Granata R; Miceli R; Locati L; Licitra L; Bossi P
Oral Oncol; 2017 Jun; 69():33-37. PubMed ID: 28559018
[TBL] [Abstract][Full Text] [Related]
36. Panitumumab as an effective maintenance treatment in metastatic squamous cell carcinoma of the head and neck.
Herrera Gómez RG; Saleh K; Mayache L; Iacob M; Baste N; Even C
Oral Oncol; 2021 Jan; 112():104984. PubMed ID: 32888816
[No Abstract] [Full Text] [Related]
37. Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains?
Jelinek MJ; Vokes EE
J Clin Oncol; 2019 Nov; 37(31):2807-2814. PubMed ID: 31483688
[No Abstract] [Full Text] [Related]
38. Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience.
Araki D; Redman MW; Martins R; Eaton K; Baik C; Chow L; Goulart B; Lee S; Santana-Davila R; Liao J; Parvathaneni U; Laramore G; Futran N; Mendez E; Bhrany A; Rodriguez CP
Head Neck; 2016 Sep; 38(9):1318-23. PubMed ID: 27061333
[TBL] [Abstract][Full Text] [Related]
39. Systemic therapy for recurrent and/or metastatic head and neck cancer: a population-based healthcare research study in Thuringia, Germany.
Morkramer L; Geitner M; Boeger D; Buentzel J; Kaftan H; Mueller AH; Ernst T; Guntinas-Lichius O
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2625-2635. PubMed ID: 33517469
[TBL] [Abstract][Full Text] [Related]
40. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F; Saba NF; Tahara M; Jayaprakash V; Lynch M; Li L; Gillison ML; Harrington KJ; Ferris RL
Cancer; 2019 Sep; 125(18):3208-3218. PubMed ID: 31246283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
